Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Exelixis Inc
(NQ:
EXEL
)
21.88
-0.30 (-1.35%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Exelixis Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021
June 15, 2021
Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an...
Via
Benzinga
Unheeding Markets
June 10, 2021
Today oil prices rose over $70.
Via
Talk Markets
Here's What Crushed Exelixis' Earnings
June 06, 2021
R&D spending is hurting earnings, but long-term investors shouldn't be worried.
Via
The Motley Fool
2 Top Biotech Stocks to Buy Right Now
May 30, 2021
One is growing revenue. And the other may soon launch its first product.
Via
The Motley Fool
Exposures
COVID-19
3 Cheap Pharmaceutical Stocks to Grab Now
May 28, 2021
The pharmaceutical industry has been the beneficiary of significant investor attention amid the COVID-19 pandemic as society turned to its products to fight the coronavirus.
Via
Talk Markets
Exposures
COVID-19
Sterling At Five-Year High
May 25, 2021
Today markets are mixed because of currency factors, with sterling bullishness against the dollar and the euro.
Via
Talk Markets
The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
May 25, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24) Bristol-Myers Squibb Company...
Via
Benzinga
Exelixis' Cabometyx, Roche's Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer Patients
May 25, 2021
Exelixis Inc (NASDAQ: EXEL) has announced results from cohort 6 of the COSMIC-021 Phase 1b trial evaluating Cabometyx (cabozantinib) in combination...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
May 24, 2021
Gainers OptiNose (NASDAQ:OPTN) stock rose...
Via
Benzinga
Is Exelixis a Buy?
May 22, 2021
Revenue growth will probably accelerate soon, but it might not be enough.
Via
The Motley Fool
What Investors Should Look for With Exelixis, DermTech, and Teladoc Health
May 21, 2021
All three healthcare stocks could have solid growth prospects.
Via
The Motley Fool
Why Is GlaxoSmithKline Selling Its Income Stream to Royalty Pharma?
May 09, 2021
Apparently, up-front capital is better than royalties on drugs the pharma doesn't have control over.
Via
The Motley Fool
Exelixis Inc (EXEL) Q1 2021 Earnings Call Transcript
May 07, 2021
EXEL earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Exelixis: Q1 Earnings Insights
May 06, 2021
Shares of Exelixis (NASDAQ:EXEL) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 52.63% over the past year...
Via
Benzinga
The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split
April 15, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14) 10x Genomics, Inc. (NASDAQ...
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.